Home » Stocks » RGEN

Repligen Corporation (RGEN)

Stock Price: $215.47 USD 3.22 (1.52%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $216.00 +0.53 (0.25%) Jan 15, 7:54 PM
Market Cap 11.71B
Revenue (ttm) 327.09M
Net Income (ttm) 43.83M
Shares Out 52.55M
EPS (ttm) 0.83
PE Ratio 261.18
Forward PE 212.77
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $215.47
Previous Close $212.25
Change ($) 3.22
Change (%) 1.52%
Day's Open 213.75
Day's Range 212.40 - 217.78
Day's Volume 417,738
52-Week Range 84.96 - 217.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 2 days ago

The tailwinds behind the company's gains aren't going anywhere.

GlobeNewsWire - 1 week ago

WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will prese...

The Motley Fool - 2 weeks ago

The bioprocessing technology company gained momentum during the coronavirus pandemic.

Zacks Investment Research - 3 weeks ago

Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.

Other stocks mentioned: AZN, LHCG, QDEL
Zacks Investment Research - 4 weeks ago

Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming releases.

Other stocks mentioned: CCRN, NTAP, OC, SPB
Zacks Investment Research - 1 month ago

Is (RGEN) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1....

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock a...

Seeking Alpha - 1 month ago

Repligen is a "pick-and-shovel" play in the bioprocessing industry. Repligen heavily invests in single-use products for use in downstream continuous manufacturing processes, which are two of t...

GlobeNewsWire - 1 month ago

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common ...

Zacks Investment Research - 1 month ago

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 month ago

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: ARPO, TCON
Zacks Investment Research - 1 month ago

Is (RGEN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 2 months ago

Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Investors Business Daily - 2 months ago

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Other stocks mentioned: IDXX, QDEL, VEEV
Zacks Investment Research - 2 months ago

These top-ranked stocks are likely to beat on bottom line in their next releases.

Other stocks mentioned: BJ, DG, HOLX, PH
Investors Business Daily - 2 months ago

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Other stocks mentioned: ALGN, PODD, QDEL, RMD
The Motley Fool - 2 months ago

The bioprocessing technology company is having a great year.

InvestorPlace - 2 months ago

Repligen stock jumped 9% on the heels of the report to a new 52-week high of $203.90 today. And Louis Navellier sees a lot more upside for the company.

Seeking Alpha - 2 months ago

Repligen Corporation's (RGEN) CEO Tony Hunt on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Repligen (RGEN) delivered earnings and revenue surprises of 42.86% and 8.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entere...

Zacks Investment Research - 2 months ago

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -

Investors Business Daily - 3 months ago

Stocks Rally As Trump Set To Leave Hospital; Repligen, United Rentals, Marvell Tech Break Out

Trumps scheduled to leave the hospital and stocks recover from Friday’s sell off. Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, i...

Other stocks mentioned: MRVL, URI
Zacks Investment Research - 3 months ago

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Other stocks mentioned: BGNE, EBS, HZNP
GlobeNewsWire - 3 months ago

WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Nav...

Seeking Alpha - 3 months ago

Repligen: A Niche Play On Biologics

Seeking Alpha - 3 months ago

Repligen hasn't seen quite the same tailwind from COVID-19 as some of its larger, more diversified rivals, but pandemic-related product development is still adding about 10% to sales.

InvestorPlace - 4 months ago

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

Other stocks mentioned: AZN, HZNP, LLY, RDY, ZTS
Zacks Investment Research - 4 months ago

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen Corporation (RGEN).

Zacks Investment Research - 4 months ago

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Investors Business Daily - 4 months ago

Nasdaq Soars To New High In Heavy Volume

Stocks splits boosted shares of Tesla and Apple Monday, but several other stocks scored big gains.

Other stocks mentioned: CRWD, WST
Zacks Investment Research - 4 months ago

These top-ranked stocks are likely to beat on their bottom line in the next releases.

Other stocks mentioned: BJ, EAT, NBL, W
Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for August 13th

Other stocks mentioned: BLDR, OSB
The Motley Fool - 5 months ago

The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.

Zacks Investment Research - 5 months ago

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Seeking Alpha - 5 months ago

Repligen Corporation's (RGEN) CEO Tony Hunt on Q2 2020 Results - Earnings Call Transcript

Investors Business Daily - 5 months ago

Growth Stocks Lift Nasdaq To Another Day Of Outperformance

Earnings reports were in focus again, with Qorvo, Repligen and Teladoc making big moves

Other stocks mentioned: QRVO, TDOC
Investors Business Daily - 5 months ago

Repligen stock broke out Friday after the maker of products and services designed to speed development of coronavirus treatments posted an earnings beat and raised its 2020 outlook. The post I...

Zacks Investment Research - 5 months ago

Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 5 months ago

Repligen is building a base and near a possible buy range ahead of its next quarterly earnings report, expected on or around Jul. 30. The post Coronavirus Play Repligen Near Buy Zone With Earn...

Zacks Investment Research - 5 months ago

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Is (RGEN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 5 months ago

EXEL vs. RGEN: Which Stock Is the Better Value Option?

Other stocks mentioned: EXEL
GlobeNewsWire - 6 months ago

Webcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT

The Motley Fool - 6 months ago

Investors have come to value the company's resilience in an uncertain year.

Zacks Investment Research - 6 months ago

LGND vs. RGEN: Which Stock Is the Better Value Option?

Other stocks mentioned: LGND
The Motley Fool - 6 months ago

In a low interest rate environment, acquisition targets in growth markets are likely to attract bidders.

Other stocks mentioned: AAON, CGNX
GlobeNewsWire - 6 months ago

Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high thro... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1981
CEO
Anthony Hunt
Employees
761
Stock Exchange
NASDAQ
Ticker Symbol
RGEN
Full Company Profile

Financial Performance

In 2019, Repligen's revenue was $270.25 million, an increase of 39.28% compared to the previous year's $194.03 million. Earnings were $21.41 million, an increase of 28.85%.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Repligen stock is "Strong Buy." The 12-month stock price forecast is 211.50, which is a decrease of -1.84% from the latest price.

Price Target
$211.50
(-1.84% downside)
Analyst Consensus: Strong Buy